Utilización de la IA en la regulación de los medicamentos: uso de grandes modelos lingüísticos (LLM)
https://www.ema.europa.eu/en/news/harnessing-ai-medicines-regulation-use-large-language-models-llms
https://www.ema.europa.eu/en/news/harnessing-ai-medicines-regulation-use-large-language-models-llms
Actualizaciones: Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with final revision 3 of Module XVI on risk minimisation measures and its Addendum II on their effectiveness evaluation, and revision 5 of Annex I on definitions Guideline on good pharmacovigilance practices (GVP)…
https://ansm.sante.fr/actualites/reglements-europeens-relatifs-aux-dispositifs-medicaux-et-de-diagnostics-in-vitro-publication-dun-consensus-statement-a-destination-de-la-commission-europeenne
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024
https://ansm.sante.fr/actualites/les-beaux-jours-arrivent-alors-que-devez-vous-savoir-sur-lutilisation-de-vos-produits-de-sante-en-ete
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024
https://www.ema.europa.eu/en/news/faster-access-clinical-trial-information-europe